[1]
Zai G, Barta C, Cath D, Eapen V, Geller D, Grünblatt E. New insights and perspectives on the genetics of obsessive-compulsive disorder. Psychiatric genetics. 2019 Oct:29(5):142-151. doi: 10.1097/YPG.0000000000000230. Epub
[PubMed PMID: 31464995]
Level 3 (low-level) evidence
[2]
Strom NI, Soda T, Mathews CA, Davis LK. A dimensional perspective on the genetics of obsessive-compulsive disorder. Translational psychiatry. 2021 Jul 21:11(1):401. doi: 10.1038/s41398-021-01519-z. Epub 2021 Jul 21
[PubMed PMID: 34290223]
Level 3 (low-level) evidence
[3]
Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, van den Heuvel OA, Simpson HB. Obsessive-compulsive disorder. Nature reviews. Disease primers. 2019 Aug 1:5(1):52. doi: 10.1038/s41572-019-0102-3. Epub 2019 Aug 1
[PubMed PMID: 31371720]
[4]
Blanco-Vieira T, Radua J, Marcelino L, Bloch M, Mataix-Cols D, do Rosário MC. The genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis. Translational psychiatry. 2023 Jun 28:13(1):230. doi: 10.1038/s41398-023-02433-2. Epub 2023 Jun 28
[PubMed PMID: 37380645]
Level 1 (high-level) evidence
[5]
Mataix-Cols D, Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. The American journal of psychiatry. 2005 Feb:162(2):228-38
[PubMed PMID: 15677583]
[6]
Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF. Meta-analysis of the symptom structure of obsessive-compulsive disorder. The American journal of psychiatry. 2008 Dec:165(12):1532-42. doi: 10.1176/appi.ajp.2008.08020320. Epub 2008 Oct 15
[PubMed PMID: 18923068]
Level 1 (high-level) evidence
[7]
Taylor S, McKay D, Miguel EC, De Mathis MA, Andrade C, Ahuja N, Sookman D, Kwon JS, Huh MJ, Riemann BC, Cottraux J, O'Connor K, Hale LR, Abramowitz JS, Fontenelle LF, Storch EA. Musical obsessions: a comprehensive review of neglected clinical phenomena. Journal of anxiety disorders. 2014 Aug:28(6):580-9. doi: 10.1016/j.janxdis.2014.06.003. Epub 2014 Jun 16
[PubMed PMID: 24997394]
[8]
Greenberg D, Huppert JD. Scrupulosity: a unique subtype of obsessive-compulsive disorder. Current psychiatry reports. 2010 Aug:12(4):282-9. doi: 10.1007/s11920-010-0127-5. Epub
[PubMed PMID: 20544313]
[9]
Fornaro M, Gabrielli F, Albano C, Fornaro S, Rizzato S, Mattei C, Solano P, Vinciguerra V, Fornaro P. Obsessive-compulsive disorder and related disorders: a comprehensive survey. Annals of general psychiatry. 2009 May 18:8():13. doi: 10.1186/1744-859X-8-13. Epub 2009 May 18
[PubMed PMID: 19450269]
Level 3 (low-level) evidence
[10]
Hollander E, Braun A, Simeon D. Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders. Depression and anxiety. 2008:25(4):317-29. doi: 10.1002/da.20500. Epub
[PubMed PMID: 18412058]
Level 3 (low-level) evidence
[11]
Veale D, Roberts A. Obsessive-compulsive disorder. BMJ (Clinical research ed.). 2014 Apr 7:348():g2183. doi: 10.1136/bmj.g2183. Epub 2014 Apr 7
[PubMed PMID: 24709802]
[12]
Fernandez TV, Leckman JF, Pittenger C. Genetic susceptibility in obsessive-compulsive disorder. Handbook of clinical neurology. 2018:148():767-781. doi: 10.1016/B978-0-444-64076-5.00049-1. Epub
[PubMed PMID: 29478613]
[13]
Goodman WK, Storch EA, Sheth SA. Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder. The American journal of psychiatry. 2021 Jan 1:178(1):17-29. doi: 10.1176/appi.ajp.2020.20111601. Epub
[PubMed PMID: 33384007]
[14]
Mahjani B, Klei L, Hultman CM, Larsson H, Devlin B, Buxbaum JD, Sandin S, Grice DE. Maternal Effects as Causes of Risk for Obsessive-Compulsive Disorder. Biological psychiatry. 2020 Jun 15:87(12):1045-1051. doi: 10.1016/j.biopsych.2020.01.006. Epub 2020 Jan 22
[PubMed PMID: 32199606]
[15]
Escobar AP, Wendland JR, Chávez AE, Moya PR. The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder. Frontiers in pharmacology. 2019:10():1362. doi: 10.3389/fphar.2019.01362. Epub 2019 Nov 15
[PubMed PMID: 31803055]
[16]
Yuste R. From the neuron doctrine to neural networks. Nature reviews. Neuroscience. 2015 Aug:16(8):487-97. doi: 10.1038/nrn3962. Epub 2015 Jul 8
[PubMed PMID: 26152865]
[17]
Maraone A, Tarsitani L, Pinucci I, Pasquini M. Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects? World journal of psychiatry. 2021 Sep 19:11(9):568-580. doi: 10.5498/wjp.v11.i9.568. Epub 2021 Sep 19
[PubMed PMID: 34631461]
[18]
Shitova AD, Zharikova TS, Kovaleva ON, Luchina AM, Aktemirov AS, Olsufieva AV, Sinelnikov MY, Pontes-Silva A, Zharikov YO. Tourette syndrome and obsessive-compulsive disorder: A comprehensive review of structural alterations and neurological mechanisms. Behavioural brain research. 2023 Sep 13:453():114606. doi: 10.1016/j.bbr.2023.114606. Epub 2023 Jul 30
[PubMed PMID: 37524204]
[19]
Bird JS, Shah E, Shotbolt P. Epilepsy and concomitant obsessive-compulsive disorder. Epilepsy & behavior case reports. 2018:10():106-110. doi: 10.1016/j.ebcr.2018.07.001. Epub 2018 Jul 20
[PubMed PMID: 30271707]
Level 3 (low-level) evidence
[20]
Parmar A, Verma R. A Case of Obsessive-Compulsive Disorder Comorbid with Miyoshi Myopathy. Indian journal of psychological medicine. 2018 Jan-Feb:40(1):86-88. doi: 10.4103/IJPSYM.IJPSYM_1_17. Epub
[PubMed PMID: 29403136]
Level 3 (low-level) evidence
[21]
Simpson HB, Slifstein M, Bender J Jr, Xu X, Hackett E, Maher MJ, Abi-Dargham A. Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907. Biological psychiatry. 2011 Nov 1:70(9):897-904. doi: 10.1016/j.biopsych.2011.06.023. Epub
[PubMed PMID: 21855857]
[22]
Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2014 Mar:24(3):375-80. doi: 10.1016/j.euroneuro.2013.12.003. Epub 2013 Dec 11
[PubMed PMID: 24406025]
[23]
Sakurai H, Dording C, Yeung A, Foster S, Jain F, Chang T, Trinh NH, Bernard R, Boyden S, Iqbal SZ, Wilkinson ST, Mathew SJ, Mischoulon D, Fava M, Cusin C. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. Journal of affective disorders. 2019 Nov 1:258():102-108. doi: 10.1016/j.jad.2019.06.065. Epub 2019 Jul 2
[PubMed PMID: 31400624]
[24]
Grassi G, Cecchelli C, Vignozzi L, Pacini S. Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder. Journal of experimental pharmacology. 2020:12():695-706. doi: 10.2147/JEP.S255375. Epub 2021 Jan 5
[PubMed PMID: 33447096]
[25]
Jalal B, Chamberlain SR, Sahakian BJ. Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction. Brain and behavior. 2023 Jun:13(6):e3000. doi: 10.1002/brb3.3000. Epub 2023 May 3
[PubMed PMID: 37137502]
[26]
Grant JE, Hook R, Valle S, Chesivoir E, Chamberlain SR. Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial. International clinical psychopharmacology. 2021 Sep 1:36(5):225-229. doi: 10.1097/YIC.0000000000000368. Epub
[PubMed PMID: 34310432]
Level 1 (high-level) evidence
[27]
Murphy TK, Patel PD, McGuire JF, Kennel A, Mutch PJ, Parker-Athill EC, Hanks CE, Lewin AB, Storch EA, Toufexis MD, Dadlani GH, Rodriguez CA. Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotype. Journal of child and adolescent psychopharmacology. 2015 Feb:25(1):14-25. doi: 10.1089/cap.2014.0062. Epub 2014 Oct 14
[PubMed PMID: 25314221]
[28]
Xu J, Liu RJ, Fahey S, Frick L, Leckman J, Vaccarino F, Duman RS, Williams K, Swedo S, Pittenger C. Antibodies From Children With PANDAS Bind Specifically to Striatal Cholinergic Interneurons and Alter Their Activity. The American journal of psychiatry. 2021 Jan 1:178(1):48-64. doi: 10.1176/appi.ajp.2020.19070698. Epub 2020 Jun 16
[PubMed PMID: 32539528]
[29]
Abramowitz JS. The psychological treatment of obsessive-compulsive disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2006 Jun:51(7):407-16
[PubMed PMID: 16838822]
[30]
Baxter AJ, Vos T, Scott KM, Ferrari AJ, Whiteford HA. The global burden of anxiety disorders in 2010. Psychological medicine. 2014 Aug:44(11):2363-74. doi: 10.1017/S0033291713003243. Epub 2014 Jan 22
[PubMed PMID: 24451993]
[31]
Fairbrother N, Collardeau F, Albert AYK, Challacombe FL, Thordarson DS, Woody SR, Janssen PA. High Prevalence and Incidence of Obsessive-Compulsive Disorder Among Women Across Pregnancy and the Postpartum. The Journal of clinical psychiatry. 2021 Mar 23:82(2):. pii: 20m13398. doi: 10.4088/JCP.20m13398. Epub 2021 Mar 23
[PubMed PMID: 34033273]
[32]
Fawcett EJ, Power H, Fawcett JM. Women Are at Greater Risk of OCD Than Men: A Meta-Analytic Review of OCD Prevalence Worldwide. The Journal of clinical psychiatry. 2020 Jun 23:81(4):. pii: 19r13085. doi: 10.4088/JCP.19r13085. Epub 2020 Jun 23
[PubMed PMID: 32603559]
[33]
Senter MS, Patel SR, Dixon LB, Myers RW, Simpson HB. Defining and Addressing Gaps in Care for Obsessive-Compulsive Disorder in the United States. Psychiatric services (Washington, D.C.). 2021 Jul 1:72(7):784-793. doi: 10.1176/appi.ps.202000296. Epub 2021 May 7
[PubMed PMID: 33957763]
[34]
Bruin WB, Taylor L, Thomas RM, Shock JP, Zhutovsky P, Abe Y, Alonso P, Ameis SH, Anticevic A, Arnold PD, Assogna F, Benedetti F, Beucke JC, Boedhoe PSW, Bollettini I, Bose A, Brem S, Brennan BP, Buitelaar JK, Calvo R, Cheng Y, Cho KIK, Dallaspezia S, Denys D, Ely BA, Feusner JD, Fitzgerald KD, Fouche JP, Fridgeirsson EA, Gruner P, Gürsel DA, Hauser TU, Hirano Y, Hoexter MQ, Hu H, Huyser C, Ivanov I, James A, Jaspers-Fayer F, Kathmann N, Kaufmann C, Koch K, Kuno M, Kvale G, Kwon JS, Liu Y, Lochner C, Lázaro L, Marques P, Marsh R, Martínez-Zalacaín I, Mataix-Cols D, Menchón JM, Minuzzi L, Moreira PS, Morer A, Morgado P, Nakagawa A, Nakamae T, Nakao T, Narayanaswamy JC, Nurmi EL, O'Neill J, Pariente JC, Perriello C, Piacentini J, Piras F, Piras F, Reddy YCJ, Rus-Oswald OG, Sakai Y, Sato JR, Schmaal L, Shimizu E, Simpson HB, Soreni N, Soriano-Mas C, Spalletta G, Stern ER, Stevens MC, Stewart SE, Szeszko PR, Tolin DF, Venkatasubramanian G, Wang Z, Yun JY, van Rooij D, ENIGMA-OCD Working Group, Thompson PM, van den Heuvel OA, Stein DJ, van Wingen GA. Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters. Translational psychiatry. 2020 Oct 8:10(1):342. doi: 10.1038/s41398-020-01013-y. Epub 2020 Oct 8
[PubMed PMID: 33033241]
[35]
de Oliveira KC, Grinberg LT, Hoexter MQ, Brentani H, Suemoto CK, Nery FG, Lima LC, Alho ATDL, Farfel JM, Ferretti-Rebustini REL, Leite REP, Moretto AC, da Silva AV, Lafer B, Miguel EC, Nitrini R, Jacob-Filho W, Heinsen H, Pasqualucci CA. Layer-specific reduced neuronal density in the orbitofrontal cortex of older adults with obsessive-compulsive disorder. Brain structure & function. 2019 Jan:224(1):191-203. doi: 10.1007/s00429-018-1752-8. Epub 2018 Oct 8
[PubMed PMID: 30298291]
[36]
Krebs G, Heyman I. Obsessive-compulsive disorder in children and adolescents. Archives of disease in childhood. 2015 May:100(5):495-9. doi: 10.1136/archdischild-2014-306934. Epub 2014 Nov 14
[PubMed PMID: 25398447]
[37]
Heyman I, Mataix-Cols D, Fineberg NA. Obsessive-compulsive disorder. BMJ (Clinical research ed.). 2006 Aug 26:333(7565):424-9
[PubMed PMID: 16931840]
[38]
Schruers K, Baldi S, van den Heuvel T, Goossens L, Luyten L, Leentjens AFG, Ackermans L, Temel Y, Viechtbauer W. The effects of deep-brain non-stimulation in severe obsessive-compulsive disorder: an individual patient data meta-analysis. Translational psychiatry. 2019 Aug 5:9(1):183. doi: 10.1038/s41398-019-0522-6. Epub 2019 Aug 5
[PubMed PMID: 31383848]
Level 1 (high-level) evidence
[39]
Öst LG, Havnen A, Hansen B, Kvale G. Cognitive behavioral treatments of obsessive-compulsive disorder. A systematic review and meta-analysis of studies published 1993-2014. Clinical psychology review. 2015 Aug:40():156-69. doi: 10.1016/j.cpr.2015.06.003. Epub 2015 Jun 14
[PubMed PMID: 26117062]
Level 1 (high-level) evidence
[40]
Öst LG, Riise EN, Wergeland GJ, Hansen B, Kvale G. Cognitive behavioral and pharmacological treatments of OCD in children: A systematic review and meta-analysis. Journal of anxiety disorders. 2016 Oct:43():58-69. doi: 10.1016/j.janxdis.2016.08.003. Epub 2016 Aug 13
[PubMed PMID: 27632568]
Level 1 (high-level) evidence
[41]
Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017 Apr 4:317(13):1358-1367. doi: 10.1001/jama.2017.2200. Epub
[PubMed PMID: 28384832]
Level 3 (low-level) evidence
[42]
Kvale G, Hansen B, Björgvinsson T, Børtveit T, Hagen K, Haseth S, Kristensen UB, Launes G, Ressler KJ, Solem S, Strand A, van den Heuvel OA, Öst LG. Successfully treating 90 patients with obsessive compulsive disorder in eight days: the Bergen 4-day treatment. BMC psychiatry. 2018 Oct 4:18(1):323. doi: 10.1186/s12888-018-1887-4. Epub 2018 Oct 4
[PubMed PMID: 30286745]
[43]
Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). The Cochrane database of systematic reviews. 2008 Jan 23:2008(1):CD001765. doi: 10.1002/14651858.CD001765.pub3. Epub 2008 Jan 23
[PubMed PMID: 18253995]
Level 1 (high-level) evidence
[44]
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular psychiatry. 2010 Aug:15(8):850-5. doi: 10.1038/mp.2009.50. Epub 2009 May 26
[PubMed PMID: 19468281]
Level 1 (high-level) evidence
[45]
Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Current medical research and opinion. 2007 Apr:23(4):701-11
[PubMed PMID: 17407626]
Level 1 (high-level) evidence
[46]
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal of clinical psychiatry. 2016 May:77(5):e605-11. doi: 10.4088/JCP.14r09758. Epub
[PubMed PMID: 27249090]
Level 1 (high-level) evidence
[47]
Varigonda AL, Jakubovski E, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2016 Oct:55(10):851-859.e2. doi: 10.1016/j.jaac.2016.07.768. Epub 2016 Aug 4
[PubMed PMID: 27663940]
Level 1 (high-level) evidence
[48]
da Conceição Costa DL, Shavitt RG, Castro Cesar RC, Joaquim MA, Borcato S, Valério C, Miguel EC, Diniz JB. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. Journal of psychiatric research. 2013 Nov:47(11):1700-7. doi: 10.1016/j.jpsychires.2013.07.006. Epub 2013 Aug 13
[PubMed PMID: 23948637]
[49]
Batelaan NM, Bosman RC, Muntingh A, Scholten WD, Huijbregts KM, van Balkom AJLM. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ (Clinical research ed.). 2017 Sep 13:358():j3927. doi: 10.1136/bmj.j3927. Epub 2017 Sep 13
[PubMed PMID: 28903922]
Level 1 (high-level) evidence
[50]
Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L. Clinical predictors of drug response in obsessive-compulsive disorder. Journal of clinical psychopharmacology. 2001 Oct:21(5):488-92
[PubMed PMID: 11593074]
[51]
Albert U, Carmassi C, Cosci F, De Cori D, Di Nicola M, Ferrari S, Poloni N, Tarricone I, Fiorillo A. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. International clinical psychopharmacology. 2016 Sep:31(5):249-58. doi: 10.1097/YIC.0000000000000127. Epub
[PubMed PMID: 26974213]
[52]
Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. The international journal of neuropsychopharmacology. 2015 May 4:18(9):. pii: pyv047. doi: 10.1093/ijnp/pyv047. Epub 2015 May 4
[PubMed PMID: 25939614]
Level 1 (high-level) evidence
[53]
Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. Journal of clinical psychopharmacology. 2011 Dec:31(6):763-8. doi: 10.1097/JCP.0b013e3182367aee. Epub
[PubMed PMID: 22020357]
Level 1 (high-level) evidence
[54]
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal of clinical psychiatry. 2017 Jul:78(7):e766-e773. doi: 10.4088/JCP.16m11101. Epub
[PubMed PMID: 28617566]
Level 1 (high-level) evidence
[55]
Dunlop K, Woodside B, Olmsted M, Colton P, Giacobbe P, Downar J. Reductions in Cortico-Striatal Hyperconnectivity Accompany Successful Treatment of Obsessive-Compulsive Disorder with Dorsomedial Prefrontal rTMS. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2016 Apr:41(5):1395-403. doi: 10.1038/npp.2015.292. Epub 2015 Oct 6
[PubMed PMID: 26440813]
[56]
Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. The American journal of psychiatry. 2019 Nov 1:176(11):931-938. doi: 10.1176/appi.ajp.2019.18101180. Epub 2019 May 21
[PubMed PMID: 31109199]
Level 1 (high-level) evidence
[57]
McCathern AG, Mathai DS, Cho RY, Goodman WK, Storch EA. Deep transcranial magnetic stimulation for obsessive compulsive disorder. Expert review of neurotherapeutics. 2020 Oct:20(10):1029-1036. doi: 10.1080/14737175.2020.1798232. Epub 2020 Aug 1
[PubMed PMID: 32684005]
[58]
Brown LT,Mikell CB,Youngerman BE,Zhang Y,McKhann GM 2nd,Sheth SA, Dorsal anterior cingulotomy and anterior capsulotomy for severe, refractory obsessive-compulsive disorder: a systematic review of observational studies. Journal of neurosurgery. 2016 Jan
[PubMed PMID: 26252455]
Level 1 (high-level) evidence
[59]
Miguel EC, Lopes AC, McLaughlin NCR, Norén G, Gentil AF, Hamani C, Shavitt RG, Batistuzzo MC, Vattimo EFQ, Canteras M, De Salles A, Gorgulho A, Salvajoli JV, Fonoff ET, Paddick I, Hoexter MQ, Lindquist C, Haber SN, Greenberg BD, Sheth SA. Evolution of gamma knife capsulotomy for intractable obsessive-compulsive disorder. Molecular psychiatry. 2019 Feb:24(2):218-240. doi: 10.1038/s41380-018-0054-0. Epub 2018 May 9
[PubMed PMID: 29743581]
[60]
Denys D, Graat I, Mocking R, de Koning P, Vulink N, Figee M, Ooms P, Mantione M, van den Munckhof P, Schuurman R. Efficacy of Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Refractory Obsessive-Compulsive Disorder: A Clinical Cohort of 70 Patients. The American journal of psychiatry. 2020 Mar 1:177(3):265-271. doi: 10.1176/appi.ajp.2019.19060656. Epub 2020 Jan 7
[PubMed PMID: 31906709]
[61]
Li N, Baldermann JC, Kibleur A, Treu S, Akram H, Elias GJB, Boutet A, Lozano AM, Al-Fatly B, Strange B, Barcia JA, Zrinzo L, Joyce E, Chabardes S, Visser-Vandewalle V, Polosan M, Kuhn J, Kühn AA, Horn A. A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder. Nature communications. 2020 Jul 3:11(1):3364. doi: 10.1038/s41467-020-16734-3. Epub 2020 Jul 3
[PubMed PMID: 32620886]
[62]
Tyagi H, Apergis-Schoute AM, Akram H, Foltynie T, Limousin P, Drummond LM, Fineberg NA, Matthews K, Jahanshahi M, Robbins TW, Sahakian BJ, Zrinzo L, Hariz M, Joyce EM. A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects. Biological psychiatry. 2019 May 1:85(9):726-734. doi: 10.1016/j.biopsych.2019.01.017. Epub 2019 Jan 30
[PubMed PMID: 30853111]
Level 1 (high-level) evidence
[63]
Meier SM, Mattheisen M, Mors O, Schendel DE, Mortensen PB, Plessen KJ. Mortality Among Persons With Obsessive-Compulsive Disorder in Denmark. JAMA psychiatry. 2016 Mar:73(3):268-274. doi: 10.1001/jamapsychiatry.2015.3105. Epub
[PubMed PMID: 26818216]
[64]
Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M, Jenkins R, Lewis G, Meltzer H, Singleton N. Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. The American journal of psychiatry. 2006 Nov:163(11):1978-85
[PubMed PMID: 17074950]
Level 3 (low-level) evidence
[65]
Bowen R, Rahman H, Dong LY, Khalaj S, Baetz M, Peters E, Balbuena L. Suicidality in People With Obsessive-Compulsive Symptoms or Personality Traits. Frontiers in psychiatry. 2018:9():747. doi: 10.3389/fpsyt.2018.00747. Epub 2019 Jan 14
[PubMed PMID: 30692943]
[66]
Nakao T, Okada K, Kanba S. Neurobiological model of obsessive-compulsive disorder: evidence from recent neuropsychological and neuroimaging findings. Psychiatry and clinical neurosciences. 2014 Aug:68(8):587-605. doi: 10.1111/pcn.12195. Epub 2014 Jun 18
[PubMed PMID: 24762196]
[67]
Fineberg NA, Apergis-Schoute AM, Vaghi MM, Banca P, Gillan CM, Voon V, Chamberlain SR, Cinosi E, Reid J, Shahper S, Bullmore ET, Sahakian BJ, Robbins TW. Mapping Compulsivity in the DSM-5 Obsessive Compulsive and Related Disorders: Cognitive Domains, Neural Circuitry, and Treatment. The international journal of neuropsychopharmacology. 2018 Jan 1:21(1):42-58. doi: 10.1093/ijnp/pyx088. Epub
[PubMed PMID: 29036632]
[68]
Perris F, Cipolla S, Catapano P, Sampogna G, Luciano M, Giallonardo V, Del Vecchio V, Fabrazzo M, Fiorillo A, Catapano F. Duration of Untreated Illness in Patients with Obsessive-Compulsive Disorder and Its Impact on Long-Term Outcome: A Systematic Review. Journal of personalized medicine. 2023 Sep 29:13(10):. doi: 10.3390/jpm13101453. Epub 2023 Sep 29
[PubMed PMID: 37888064]
Level 1 (high-level) evidence
[69]
Van Ameringen M, Patterson B, Simpson W. DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria. Depression and anxiety. 2014 Jun:31(6):487-93. doi: 10.1002/da.22259. Epub 2014 Mar 10
[PubMed PMID: 24616177]